MDS 2022 | Functional imaging and tau PET tracers for diagnosing PSP & CBD

Rodolfo Savica, MD, PhD, Mayo Clinic, Rochester, MN, outlines the current use of imaging biomarkers for the diagnosis of tauopathies, particularly progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), and the development of PET tracer. Structural imaging studies are widely used to aid diagnosis; however, functional imaging techniques, such as PET scans, may be cardinal in differentiating tauopathies and/or movement disorders. The development and validation of tau PET tracers can become an important diagnostic tool for the differential diagnosis of tauopathies, but further research is needed. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.